Opdivo (nivolumab)

pCPA File Number: 21791

Negotiation Status:

Concluded with an LOI

Indication(s):

Opdivo — in combination with fluoropyrimidine- and platinum-containing chemotherapy — for the treatment of adult patients with advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma

Sponsor/Manufacturer:

Bristol Myers Squibb Canada Inc.

CADTH Project Number:

PC0259

pCPA Engagement Letter Issued:

2022-06-28

Negotiation Process Concluded:

2022-08-25